SingleFlowEx CD19 APC

SingleFlowEx is fluorochrome-labeled monoclonal antibody single reagent for use in laboratory-developed multicolor flow cytometry tests in order to examine human clinical samples. SingleFlowEx can be used in various multicolor combinations. Laboratory shall establish the SingleFlowEx performance characteristics in conjunction with other reagents in normal and pathological samples.

Product Specifications

Certification

RUO (GMP)

Clone

LT19

Applications

FC (QC tested)

Concentration

0.035 mg/mL

Format

APC

Buffer

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Components

1 vial of monoclonal antibody reagent.The content (1 mL) is sufficient for min. 100 Tests.

References & Citations

*Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15;106 (10) :3567-74. Epub 2005 Jul 26., URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16046525&query_hl=14&itool=pubmed_DocSum , *Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2013 Sep 13. doi: 10.1111/ijlh.12149., URL: http://www.ncbi.nlm.nih.gov/pubmed/24028768 , *Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sumnik Z, Kolouskova S, Spisek R, Sediva A: Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin Immunol. 2014 Jul;153 (1) :49-55., URL: http://www.ncbi.nlm.nih.gov/pubmed/24709112 , *Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1;171 (7) :3697-704. , URL: https://www.ncbi.nlm.nih.gov/pubmed/14500668?dopt=, *Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M: Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009 Jan;58 (1) :138-45., URL: https://pubmed.ncbi.nlm.nih.gov/18835928/, *Weijler L, Kowarsch F, Wödlinger M, Reiter M, Maurer-Granofszky M, Schumich A, Dworzak MN: UMAP based anomaly detection for minimal residual disease quantification within acute myeloid leukemia. Cancers (Basel) 2022 Feb 11;14 (4) :898., URL: https://pubmed.ncbi.nlm.nih.gov/35205645/, *Use of this product has not been published., URL:

Other References

*Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56 (9) :3057-69., URL: https://pubmed.ncbi.nlm.nih.gov/17763445/, *van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354 (18) :1901-12., URL: https://pubmed.ncbi.nlm.nih.gov/16672701/, *Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99 (2) :584-9., URL: https://pubmed.ncbi.nlm.nih.gov/11781242/, *Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162 (12) :7088-94., URL: https://pubmed.ncbi.nlm.nih.gov/10358152/